Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting
September 09, 2020 07:45 ET
|
Radius Health Inc.
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American...
Radius Health: Enrollment Completed for Phase 3 wearABLe trial
September 08, 2020 08:00 ET
|
Radius Health Inc.
Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skinTrial success followed by regulatory approval would provide a completely unique drug...
Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference
September 02, 2020 16:15 ET
|
Radius Health Inc.
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management...
Radius Health Provides Business Update
August 25, 2020 09:00 ET
|
Radius Health Inc.
TYMLOS® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent lifeEnrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males...
Sean Murphy joins Radius Health Board of Directors
August 10, 2020 08:15 ET
|
Radius Health Inc.
WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with...
Radius Health Announces Second Quarter 2020 Operating Results
August 10, 2020 08:15 ET
|
Radius Health Inc.
TYMLOS® U.S. net sales of $50 million, with 22% year over year growth Completion of enrollment in ATOM Phase 3 expected this week Phase 3 Trials: wearABLe and EMERALD remain...
Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020
July 27, 2020 16:15 ET
|
Radius Health Inc.
WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will...
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
July 23, 2020 16:15 ET
|
Radius Health Inc.; Menarini Group
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 developmentElacestrant further strengthens Menarini’s global oncology...
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
May 27, 2020 05:00 ET
|
Radius Health Inc.
Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc....
Radius Health Announces First Quarter 2020 Operating Results
May 07, 2020 16:15 ET
|
Radius Health Inc.
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs...